Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Kai, Xie, Fachao, Wang, Fang, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733018/
https://www.ncbi.nlm.nih.gov/pubmed/36482474
http://dx.doi.org/10.1186/s13045-022-01391-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733018/
https://www.ncbi.nlm.nih.gov/pubmed/36482474
http://dx.doi.org/10.1186/s13045-022-01391-4

Ejemplares similares